JP2009543874A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543874A5
JP2009543874A5 JP2009520840A JP2009520840A JP2009543874A5 JP 2009543874 A5 JP2009543874 A5 JP 2009543874A5 JP 2009520840 A JP2009520840 A JP 2009520840A JP 2009520840 A JP2009520840 A JP 2009520840A JP 2009543874 A5 JP2009543874 A5 JP 2009543874A5
Authority
JP
Japan
Prior art keywords
composition
leukemia
subject
formula
pkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009520840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543874A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016391 external-priority patent/WO2008011113A2/en
Publication of JP2009543874A publication Critical patent/JP2009543874A/ja
Publication of JP2009543874A5 publication Critical patent/JP2009543874A5/ja
Pending legal-status Critical Current

Links

JP2009520840A 2006-07-18 2007-07-18 チアゾリジノン誘導体 Pending JP2009543874A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83189306P 2006-07-18 2006-07-18
PCT/US2007/016391 WO2008011113A2 (en) 2006-07-18 2007-07-18 Thiadiazolidinone derivatives

Publications (2)

Publication Number Publication Date
JP2009543874A JP2009543874A (ja) 2009-12-10
JP2009543874A5 true JP2009543874A5 (https=) 2011-09-01

Family

ID=38957376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520840A Pending JP2009543874A (ja) 2006-07-18 2007-07-18 チアゾリジノン誘導体

Country Status (7)

Country Link
US (2) US9180118B2 (https=)
EP (1) EP2043633B1 (https=)
JP (1) JP2009543874A (https=)
AU (1) AU2007275686B2 (https=)
CA (1) CA2658263A1 (https=)
NZ (1) NZ574619A (https=)
WO (1) WO2008011113A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
EP2211870A1 (en) * 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20090117090A1 (en) * 2007-11-01 2009-05-07 Ottawa Heart Institute Research Corporation Inhibition of glycogen synthase kinase 3 beta in arterial repair and stent re-endothelialization
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
MX388409B (es) * 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
MX376146B (es) 2015-03-17 2025-03-07 Regeneron Pharma Reactivos de acilacion de aminoacidos y metodos para usar los mismos.
AU2017295858A1 (en) * 2016-07-14 2019-01-24 Mingsight Pharmaceuticals, Inc. Treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030739A1 (en) 1997-12-16 1999-06-24 Sankyo Company, Limited Leukemia remedy
JPH11335298A (ja) * 1997-12-16 1999-12-07 Sankyo Co Ltd 白血病治療剤
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
AU783615B2 (en) * 2000-05-11 2005-11-17 Consejo Superior De Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase GSK-3
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
FI20041129A0 (fi) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20060204980A1 (en) * 2004-12-28 2006-09-14 Altieri Dario C Colorectal cancer therapies
US20070196514A1 (en) * 2006-02-21 2007-08-23 Benyi Li Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer

Similar Documents

Publication Publication Date Title
JP2009543874A5 (https=)
KR102444482B1 (ko) 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
KR102908092B1 (ko) Cxcr4 억제제의 조성물 및 제조 방법 및 용도
US10913727B2 (en) Modulators of the integrated stress pathway
JP5637852B2 (ja) ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
EP3704091B1 (en) INTEGRATED STRESS RESPONSE PATH MODULATORS
US20240307382A1 (en) Modulators of the integrated stress pathway
JP6133383B2 (ja) ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
JP6500037B2 (ja) 二環式ピラゾロン化合物および使用方法
TW202019900A (zh) Ptpn11抑制劑
RS57177B1 (sr) Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1
JP2021502388A (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
CN116554168A (zh) Cxcr4抑制剂及其用途
EP2861576A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
HUE026041T2 (en) Pyrrolo-triazinone derivatives as P13K inhibitors
JP2017508787A (ja) 医薬化合物
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
WO2016166604A1 (en) Plk4 inhibitors
JP2025519119A (ja) Ｍｅｋ阻害剤及びその使用
JP2025511161A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ
JP2009537606A5 (https=)
JP2022502378A5 (https=)
CA3116230A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds